Boehringer Ingelheim's Brian Hilberdink, President, U.S. Human Pharma, and Neerja Balachander, M.D., Ph.D., VP, U.S. Clinical Development Medical Affairs and Cardiorenal Metabolic Therapeutic Area Head, reflect on key developments and what lies ahead for cardiovascular, renal and metabolic care, including implications for obesity, liver disease and chronic kidney disease.
The following is a transcript of their conversation:
Brian Hilberdink: Neerja, I was reflecting on what an exciting time it is for Boehringer Ingelheim to really be involved in the cardio-renal-metabolic space. And it was just a reflection, we were talking before about the fact that despite all of the innovation that has happened over the past several decades, there's still so much work to be done.
Neerja Balachander: Very interesting times and exciting times, but I think it's important for us to be reminded of the gravity of the situation. Cardio-kidney-metabolic conditions affect more than a billion patients across the world and continue to be the number one cause for mortality and morbidity. In the US, 90% of adults, according to the American Heart Association, are affected at least in stage one of the cardio-kidney-metabolic conditions. So, I'm excited that we at Boehringer are taking such an active role.
